Crossmark

Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial

Crossref DOI link: https://doi.org/10.1186/s40880-017-0263-y

Published Online: 2017-12-22

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Rui-Hua

Shen, Lin http://orcid.org/0000-0002-1205-049X
Wang, Ke-Ming

Wu, Gang

Shi, Chun-Mei

Ding, Ke-Feng

Lin, Li-Zhu

Wang, Jin-Wan

Xiong, Jian-Ping

Wu, Chang-Ping

Li, Jin

Liu, Yun-Peng

Wang, Dong

Ba, Yi

Feng, Jue-Ping

Bai, Yu-Xian

Bi, Jing-Wang

Ma, Li-Wen

Lei, Jian

Yang, Qing

Yu, Hao
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct01762293 at ClinicalTrials.gov

Documents that mention this clinical trial

Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial
https://doi.org/10.1186/s40880-017-0263-y
Funding

Funding for this research was provided by:

Jiangsu Hengrui Medicine Co., Ltd.
License Information

Text and Data Mining valid from 2017-12-01

Version of Record valid from 2017-12-22
More Information

Article History

Received: 18 July 2017

Accepted: 5 December 2017

First Online: 22 December 2017

Document is current

Any future updates will be listed below